[1]许 涛a,高玉芳a,刘振社a,等.中国地区COVID-19 康复者SARS-CoV-2 特异性抗体IgG 阳性率动态变化的meta 分析[J].现代检验医学杂志,2022,37(06):134-139.[doi:10.3969/j.issn.1671-7414.2022.06.025]
　XU Taoa,GAO Yu-fanga,LIU Zhen-shea,et al.A Meta-analysis of Dynamic Change of the SARS-COV-2 Specific Antibody IgG Positive Rate in Convalescent Patients with COVID-19 in China[J].Journal of Modern Laboratory Medicine,2022,37(06):134-139.[doi:10.3969/j.issn.1671-7414.2022.06.025]
点击复制

中国地区COVID-19 康复者SARS-CoV-2 特异性抗体IgG 阳性率动态变化的meta 分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
134-139
栏目:
新型冠状病毒肺炎检验专题
出版日期:
2022-11-15

文章信息/Info

Title:
A Meta-analysis of Dynamic Change of the SARS-COV-2 Specific Antibody IgG Positive Rate in Convalescent Patients with COVID-19 in China
文章编号:
1671-7414(2022)06-134-06
作者:
许 涛1a; 高玉芳1a; 刘振社1a; 权 伟2; 杨 磊1b
(1. 咸阳市中心医院 a. 检验科；b. 生殖医学科，陕西咸阳 712000；2. 海原县人民医院检验科，宁夏海原 755200)
Author(s):
XU Tao1a;  GAO Yu-fang1a;  LIU Zhen-she1a;  QUAN Wei2;  YANG Lei1b
(1a. Department of Clinical Laboratory; 1b. Department of Reproductive Medicine, Xianyang Central Hospital, Shaanxi Xianyang 712000, China; 2. Department of Clinical Laboratory, Haiyuan County People’s Hospital, Ningxia Haiyuan 755200, China)
关键词:
新型冠状病毒病; 严重急性呼吸综合征冠状病毒2; 特异性抗体IgG; Meta 分析
分类号:
R373.19；R446.62
DOI:
10.3969/j.issn.1671-7414.2022.06.025
文献标志码:
A
摘要:
目的 了解中国地区新型冠状病毒病(coronavirus disease 2019，COVID-19)康复者严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2，SARS-CoV-2)特异性抗体IgG 阳性率的动态变化。方法 计算机检索PubMed，Embase，中国知网(CNKI)、万方数据库和维普数据库(VIP)中有关中国地区COVID-19 康复者SARS-CoV-2 特异性抗体IgG 阳性率检测相关文献，检索时间为2019 年12 月～ 2022 年2 月24 日。根据修改后的AHRQ (Agency for Healthcare Researoh and Quality, 美国卫生保健质量和研究机构) 标准评估文献质量。采用Freeman-Tukey 双反正弦转换法计算阳性率，统计分析采用StataSE15.0 软件。根据检测方法、检测片段进行亚组分析，采用Egger 法检验发表偏倚。结果 共纳入12 篇文献，IgG 检测时间为感染SARS-CoV-2 后第1 个月～第12 个月，每个月样本量总计为74 ～ 2 907 例。第1 个月IgG 阳性率为81.10%(95%CI：75.76% ～ 85.87%)，第2 个月和第3 个月阳性率最高，分别为96.35%(95%CI：93.98% ～ 98.14%)和97.23%(95%CI：94.47% ～ 99.05%)，随时间推移阳性率逐渐下降，至第12 个月为73.63%(95%CI：50.31% ～ 91.45%)。亚组分析显示不同检测方法的研究间、不同检测片段的研究间阳性率差异均有统计学意义(χ2=5.02 ～ 39.57，均P＜ 0.05)。Egger 法检验发表偏倚为差异无统计学意义(t=1.85，P =0.101)。结论 大多数SARS-CoV-2 感染者一年后仍可检出SARS-CoV-2 特异性抗体IgG。
Abstract:
Objective To investigate the dynamic changes of severe acute respiratory syndrome coronavirus 2(SARS-COV-2) specific antibody IgG positive rate in coronavirus disease 2019(COVID-19) survivors in China. Methods the relevant literatures about the positive rate of SARS-COV-2 specific antibody IgG in COVID-19 survivors in China were retrieved from PubMed, Embase, CNKI, Wanfang database and VIP database from December 2019 to February 24, 2022. The quality of the documents were assessed according the revised AHRQ(Agency for Healthcare Research and Quality) statement. Freeman-tukey double arsinusoidal conversion method was used to calculate the positive rate, and StataSE15.0 software was used for statistical analysis. Subgroup analysis was performed according to detection method and fragment, and publication bias was examined by Egger method. Results A total of 12 articles were included, IgG was detected from the first month to the twelfth month after SARS-COV-2 infection, and the total sample size ranged from 74 to 2 907 cases per month. The positive rate was the highest in the second month and the third month, 96.35% (95%CI: 93.98% ～ 98.14%) and 97.23% (95%CI: 94.47% ～ 99.05%) respectively. The positive rate decreased gradually with time, and reached 73.63% (95%CI: 50.31% ～ 91.45%) in the twelfth month. The results of subgroup analysis showed that the heterogeneity between studies with the different detection method and the different detection fragment were significant differences(χ2=5.02 ～ 39.57, all P<0.05). Egger method test published bias, and the difference was not statistically significant (t=1.85, P=0.101). Conclusion Most people , one year after infection with SARSCOV- 2, could still detect SARS-COV-2 specific antibody IgG.

参考文献/References:

[1] LU Roujiang, ZHAO Xiang, LI Juan, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. The Lancet, 2020, 395(10224): 565-574.
[2] World Health Organization. Weekly epidemiological update on COVID-19- 6 July 2022［EB/OL］. https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
[3] FONTANET A, CAUCHEMEZ S. COVID-19 herd im-munity: where are we[J]. Nature Reviews Immunology, 2020, 20(10): 583-584.
[4] ALTMANN D M, BOYTON R J. COVID-19 vaccination: the road ahead[J]. Science, 2022, 375(6585): 1127-1132.
[5] IBARRONDO F J, FULCHER J A, GOODMAN M D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19[J]. New England Journal of Medicine, 2020, 383(11): 1085-1087.
[6] ISHO B, ABE KT, ZUO M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients[J]. Sci Immunol, 2020, 5(52):eabe5511.
[7] ANAND S P, PR?VOST J, NAYRAC M, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset[J]. Cell Reports Medicine, 2021, 2(6): 100290.
[8] DESHPANDE G , KADUSKAR O , DESHPANDE K , et al. Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.[J]. International Journal of Infectious Diseases, 2021, 112:103-110.
[9] 加明明 , 刘兰 , 蔡璇 , 等．新型冠状病毒肺炎患者抗体变化：一项为期 10月的前瞻性研究 [J]．武汉大学学报 (医学版 ), 2021, 42(6)：861-866． JIA Mingming, LIU Lan, CAI Xuan, et al. Changes of antibodies in COVID-19 patients: A 10-month prospective study [J].Medical Journal of Wuhan University (Medical sciences), 2021; 42(6): 861-866.
[10] YU Siyang, AN Jianghong, LIAO Xuejiao, et al. Distinct kinetics of immunoglobulin isotypes reveal early diagnosis and disease severity of COVID-19: A 6-month follow-up[J]. Clinical and Translational Medicine, 2021, 11(3): e342.
[11] SHI Danrong, WENG Tianhao, WU Jie, et al. Dynamic characteristic analysis of antibodies in patients with COVID-19: A 13-month study[J]. Frontiers in Immunology, 2021, 12: 708184.
[12] ZHU Liguo, XU Xin, ZHU Baoli, et al. Kinetics of SARS-CoV-2 specific and neutralizing antibodies over seven months after symptom onset in COVID-19 patients[J]. Microbiology spectrum, 2021, 9(2): e0059021.
[13] ZHAN Yan, ZHU Yufang, WANG Shanshan, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 368.
[14] YAO Lin, WANG Guoli, SHEN Yuan, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection[J]. The Journal of Infectious Diseases, 2021, 224(4): 586-594.
[15] WANG Yanan, LI Jingjing, LI Huijun, et al. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients[J]. International Immunopharmacology, 2021, 90: 107271.
[16] WANG Hao, YUAN Yu, XIAO Mingzhong, et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection[J]. Cellular & Molecular Immunology, 2021, 18(7): 1832-1834.
[17] LIU Chuanmiao, YU Xiaoqi, GAO Chunming, et al. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients[J]. Journal of Medical Virology, 2021, 93(4): 2227-2233.
[18] LI Kening, HUANG Bin, WU Min, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19[J]. Nature Communications, 2020, 11(1): 6044.
[19] LI C, YU Ding, WU Xiao, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan[J]. Nature Communications, 2021, 12(1): 4144.
[20] LAU E H Y, TSANG O TY, HUI D S C, et al. Neutralizing antibody titres in SARS-CoV-2 infections[J]. Nature Communications, 2021, 12(1): 63.
[21] SHANG Jian, YE Gang, SHI Ke, et al. Structural basis of receptor recognition by SARS-CoV-2[J]. Nature, 2020, 581(787): 221-224.
[22] JACKSON C B, FARZAN M, CHEN Bing, et al. Mechanisms of SARS-CoV-2 entry into cells[J]. Nature Reviews Molecular Cell Biology, 2022, 23(1): 3-20.
[23] JEYANATHAN M, AFKHAMI S, SMAILL F, et al. Immunological considerations for COVID-19 vaccine strategies[J]. Nature Reviews Immunology, 2020, 20(10): 615-632.
[24] CAO Wuchun, LIU Wei, ZHANG Panhe, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery[J]. New England Journal of Medicine, 2007, 357(11): 1162-1163.
[25] WANG Zijun, MUECKSCH F, SCHAEFER-BABAJEW D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection[J]. Nature, 2021, 595(7867): 426-431.
[26] LUO Chunhua, LIU Min, LI Qianyuan, et al. Dynamic changes and prevalence of SARS-CoV-2 IgG/ IgM antibodies: multiple factors-based analysis[J]. International Journal of Infectious Diseases, 2021, 108: 57-62.
[27] IVERSEN K, KRISTENSEN J H, HASSELBALCH R B, et al. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months:a Danish observational cohort study of 44 000 healthcare workers[J]. Clinical Microbiology and Infection, 2022, 28(5): 710-717.
[28] KISSLER S M, TEDIJANTO C, GOLDSTEIN E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period[J]. Science, 2020, 368(6493): 860-868.
[29] ACHIRON A, GUREVICH M, FALB R, et al. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects[J]. Clinical Microbiology and Infection, 2021, 27(9): 1349. e1-1349.e6.
[30] Y?CE M, FILIZTEKIN E, ?ZKAYA K G. COVID-19 diagnosis-A review of current methods [J]. Biosens Bioelectron, 2021, 172:112752.
[31] LIAO Baolin, CHEN Zhao, ZHENG Peiyan, et al. Detection of Anti-SARS-CoV-2-S2 IgG is more sensitive than anti-RBD IgG in identifying asymptomatic COVID-19 patients [J]. Front Immunol, 2021, 12: 724763.
[32] 胡纪文 , 王恩运 , 阚丽娟 , 等．三种化学发光法检测新型冠状病毒 (SARS-CoV-2)抗体试剂盒的临床应用评价 [J].现代检验医学杂志 , 2020, 35(4): 100-105. HU Jiwen, WANG Enyun, KAN Lijuan, et al. Evaluation of clinical application of three chemiluminescence detection kits for detection of novel coronavirus(SARS-CoV-2) antibody [J]. Journal of Modern Laboratory Medicine, 2020, 35(4): 100-105.
[33] GUO Yaolin, LI Tianyi, XIA Xinyi, et al. Different profiles of antibodies and cytokines were found between severe and moderate COVID-19 patients[J]. Frontiers in Immunology, 2021, 12: 723585.

相似文献/References:

[1]杨 磊a,冯美宁a,宋海锋a,等.COVID-19 患者SARS-CoV-2 感染前后精液质量参数变化的meta 分析[J].现代检验医学杂志,2023,38(01):179.[doi:10.3969/j.issn.1671-7414.2023.01.034]
　YANG Leia,FENG Mei-ninga,SONG Hai-fenga,et al.Changes of Semen Quality Parameters before and after SARS-CoV-2 Infection in Patients with COVID-19: A Meta-Analysis[J].Journal of Modern Laboratory Medicine,2023,38(06):179.[doi:10.3969/j.issn.1671-7414.2023.01.034]
[2]许　涛a,杨　磊b,高玉芳a,等.中国地区新型冠状病毒感染者的密切接触人群SARS-CoV-2核酸阳性率的meta分析[J].现代检验医学杂志,2021,36(04):122.[doi:10.3969/j.issn.1671-7414.2021.04.026]
　XU Taoa,YANG Leib,GAO Yu-fanga,et al.SARS-CoV-2 Nucleic Acid Positive Rate among Close Contacts of thePatients Infected with Novel Coronavirus in China:A Meta-Analysis[J].Journal of Modern Laboratory Medicine,2021,36(06):122.[doi:10.3969/j.issn.1671-7414.2021.04.026]

备注/Memo

备注/Memo:
作者简介：许涛(1987-)，男，硕士，主管检验师，研究方向：临床病毒核酸诊断及其流行病学调查，E-mail：dazhuxt126@126.com。
通讯作者：杨磊(1991-)，女，硕士，主管检验师，研究方向：临床检验诊断学，E-mail：shangcl21@163.com。
更新日期/Last Update: 2022-11-15